|
| 36997747 | Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors. | Nat Cancer | 2023 |
| 30973970 | Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor. | Br J Clin Pharmacol | 2019 |
| 29985971 | Computational analysis of kinase inhibitor selectivity using structural knowledge. | Bioinformatics | 2019 |
| 31542806 | Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. | Cancer Chemother Pharmacol | 2019 |
| 29921320 | Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors. | J Immunother Cancer | 2018 |
| 30185228 | A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. | Breast Cancer Res | 2018 |
| 28664655 | Commentary on: "Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide". | Clin Transl Sci | 2017 |
| 28992562 | A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer. | Eur J Cancer | 2017 |
| 28748626 | Combining "Bottom-up" and "Top-down" Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC-0941) Pharmacokinetics. | CPT Pharmacometrics Syst Pharmacol | 2017 |
| 26924066 | Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. | Clin Transl Sci | 2016 |
| 26507723 | The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers. | Clin Pharmacokinet | 2016 |
| 24961373 | OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. | Proc Natl Acad Sci U S A | 2014 |
| 25275310 | Genome-wide discovery of drug-dependent human liver regulatory elements. | PLoS Genet | 2014 |
| 23140242 | Renal transporters in drug development. | Annu Rev Pharmacol Toxicol | 2013 |
| 23241029 | Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. | J Med Chem | 2013 |
| 23267855 | The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. | Clin Pharmacol Ther | 2013 |
| 21383772 | Discovery of regulatory elements in human ATP-binding cassette transporters through expression quantitative trait mapping. | Pharmacogenomics J | 2012 |
| 23085876 | The UCSF-FDA TransPortal: a public drug transporter database. | Clin Pharmacol Ther | 2012 |
| 21070833 | Consequences of POR mutations and polymorphisms. | Mol Cell Endocrinol | 2011 |
| 21956618 | A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. | Clin Pharmacol Ther | 2011 |
| 20940534 | Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. | Pharmacogenet Genomics | 2010 |
| 18669588 | Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. | Drug Metab Dispos | 2008 |
| 16643277 | Expanding the role of the dynein regulatory complex to non-axonemal functions: association of GAS11 with the Golgi apparatus. | Traffic | 2006 |